TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01025869

Intervention type: DEVICE
Group type: OTHER
Intervention: Cinatra™ Corolimus Eluting Coronary Stent System
Description: Stent implantation
Study: NCT03717987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc supplementation
Description: zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
Study: NCT03455361

Intervention type: PROCEDURE
Intervention: Stark Implant with low primary stability

Intervention type: PROCEDURE
Intervention: Stark Implant with low primary stability
Study: NCT04266561

Intervention type: OTHER
Group type: OTHER
Intervention: hernia repair
Description: Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
Study: NCT04179240

Intervention type: OTHER
Group type: OTHER
Intervention: audio and animated cartoon questionnaire
Description: participants were asked to complete a questionnaire audio and animated cartoon on a platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: audio and animated cartoon questionnaire
Description: participants were asked to complete a questionnaire audio and animated cartoon on a platform
Study: NCT02256787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILB 1941 ZW - single rising dose part

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILB 1941 ZW - solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILB 1941 ZW - tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILB 1941 ZW - tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized breakfast
Study: NCT01037933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Humor intervention
Description: A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-humor intervention (distraction)
Description: A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player
Study: NCT02712619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03274037

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Device for mechanical excitation by pressure waves
Description: The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields.
Study: NCT03357354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: collective workshop
Description: diet, sports games, food budget, feeling of satiety and hunger, self-image
Study: NCT00975390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: 1.2 g/kg/h

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate and protein ingestion
Description: 1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate and caffeine ingestion
Description: 1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
Study: NCT03920163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Recovery Measures
Description: Perioperative measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Measures
Description: Perioperative measures
Study: NCT00069459

Intervention type: DRUG
Group type: OTHER
Intervention: Extended-release Bupropion Hydrochloride
Description: Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
Study: NCT01311713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered per dose and schedule specified in the arm description.
Study: NCT03181048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periacetabular osteotomy
Description: The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periacetabular osteotomy with hip arthroscopy
Description: An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
Study: NCT01311713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: CEP-9722 will be administered per dose and schedule specified in the arm description.
Study: NCT03255473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
Study: NCT03755427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15μg H7N9 Vaccine
Description: The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum Hydroxide Adjuvant
Description: The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
Study: NCT03436849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESN364
Description: ESN364 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESN364
Description: ESN364 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESN364
Description: ESN364 will be administered orally.
Study: NCT04314544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TILD
Description: one 1 mL injection of study medication
Study: NCT03436849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESN364
Description: ESN364 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESN364
Description: ESN364 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT05266144

Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
Study: NCT00798772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrients and antioxidants
Description: 8 capsules twice daily for two years
Study: NCT04314544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo injections
Description: one 1 mL injection of placebo
Study: NCT00798772

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins and minerals
Description: 8 capsules twice daily for two years
Study: NCT05602155

Intervention type: PROCEDURE
Intervention: Group 1
Description: Even numbered patients will partial weight bearing after treatment,

Intervention type: PROCEDURE
Intervention: Group 1
Description: Even numbered patients will partial weight bearing after treatment,

Intervention type: PROCEDURE
Intervention: Group 2
Description: patients with odd numbers will walk with full weight bearing after treatment

Intervention type: PROCEDURE
Intervention: Group 2
Description: patients with odd numbers will walk with full weight bearing after treatment
Study: NCT02780362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prodactariv
Description: 1 tablet contains 60 mg Daclatasvir
Study: NCT03436849

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT04653376

Intervention type: PROCEDURE
Intervention: Tonsillectomy surgery
Description: The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.

Intervention type: PROCEDURE
Intervention: Tonsillectomy surgery
Description: The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
Study: NCT01342315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 33525
Description: Daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily dosing
Study: NCT04266431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: Behavioral weight loss intervention
Study: NCT03298516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCLL9718S
Description: DCLL9718S will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCLL9718S
Description: DCLL9718S will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered as per the schedule specified in the respective arm.
Study: NCT05539534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on suicide prevention
Description: Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
Study: NCT02780362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clatazev
Description: 1 tablet contains 60 mg Daclatasvir
Study: NCT05696509

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
Study: NCT00099515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY041001 (HIIP)
Description: Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
Study: NCT05696509

Intervention type: DRUG
Group type: OTHER
Intervention: Isoflurane
Description: Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
Study: NCT02993705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Chemotherapy drug
Study: NCT04101695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
Study: NCT00099515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY041001 (HIIP)
Description: Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
Study: NCT03545217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
Study: NCT01300858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGEN-001-301
Description: Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
Study: NCT00536380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg Desloratadine
Description: 5-mg desloratadine tablets, once daily for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-mg Desloratadine
Description: 10-mg desloratadine tablets, once daily for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20-mg Desloratadine
Description: 20-mg desloratadine tablets, once daily for four weeks.
Study: NCT00555867

Intervention type: DRUG
Intervention: Anastrozole
Description: oral

Intervention type: DRUG
Intervention: Anastrozole
Description: oral
Study: NCT04541641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New Reverse Drilling technique
Description: a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteotome technique
Description: a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
Study: NCT01943162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPT
Study: NCT01643291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
Study: NCT00618319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021
Description: Dose, schedule, and duration specified in protocol
Study: NCT00299702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abilify
Description: 10-30 mg once daily for 104 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidal Consta
Description: 25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
Study: NCT03795077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
Study: NCT03824899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood concentration check
Description: Blood concentration check：the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion
Study: NCT02321124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue manipulation
Description: We will apply connective tissue manipulation 5 days a week for four weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: life style advice
Description: We will apply life style advice for four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: life style advice
Description: We will apply life style advice for four weeks.
Study: NCT02930668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosanol 350mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosanol 500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03548662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyruan Plus Inj. produced by LG Life Sciences, Ltd.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
Study: NCT01280344

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipamorelin
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipamorelin
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipamorelin
Description: Intravenous (IV)
Study: NCT04359537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG
Description: Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG
Description: Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 MG
Description: Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described
Study: NCT02082366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCD monitoring of microembolic signal during procedure
Description: monitoring of microembolic signal during procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCD monitoring of microembolic signal during procedure
Description: monitoring of microembolic signal during procedure
Study: NCT01867580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.Ulta with Prontosan instillation
Description: NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V.A.C.Ulta without instillation
Description: NPWT only
Study: NCT01278862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVS veneer
Description: CAD/CAM milled porcelain veneer for Lava crown
Study: NCT00518687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710
Description: 0.5-mL single injection of V710 (60 µg)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5-mL single injection of matching placebo